查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541326

2024-2032 年生命科学人工智慧市场报告（按产品、部署、应用和地区划分）

Artificial Intelligence in Life Sciences Market Report by Offering, Deployment, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球生命科学人工智慧市场规模达24亿美元。复杂疾病盛行率的上升、人工智慧在医学影像分析中的日益采用、人工智慧与基因组学研究和分析的整合以及人工智慧与新兴技术的融合是推动市场的一些主要因素。

生命科学领域的人工智慧市场分析：

主要市场驱动力：生命科学中的人工智慧主要是由基因组序列和电子健康记录中的生物医学资料量的增加所推动的，这需要结合强大的人工智慧工具来进行有效的管理和分析。与此一致的是，人工智慧有助于加速药物发现和开发过程，从而显着减少时间和成本。此外，对临床环境中人工智慧整合的监管支援以及机器学习和计算演算法的进步进一步推动了人工智慧在生命科学市场的成长。

主要市场趋势：生命科学领域人工智慧的主要市场趋势包括人工智慧与云端运算和物联网（IoT）设备的集成，进一步增强资料可存取性和即时分析。人工智慧驱动的预测模型的开发也有一个显着的趋势，这些模型可以预测疾病进展和患者结果，从而改善临床决策。与此一致，人工智慧技术公司和製药公司之间的合作不断增加，主要目的是利用人工智慧进行药物开发和患者监测。另一个值得注意的趋势是，人们越来越关注道德人工智慧和透明演算法，以确保患者资料安全和隐私合规性。此外，在机器人流程自动化（RPA）中使用人工智慧可以简化医疗保健领域的管理任务，进一步推动人工智慧在生命科学市场的成长。

地理趋势：从地理上看，北美领先的人工智慧和生命科学市场主要得益于其先进的技术基础设施、对人工智慧和医疗保健的大量投资以及监管机构的大力支持。欧洲紧随其后，由于人工智慧在医疗保健系统中的采用增加以及政府对人工智慧研究和资料保护政策的支持，其成长显着。亚太地区正在经历显着的成长，这主要得益于医疗保健需求的成长、技术的进步以及中国、日本和印度等国家推动人工智慧发展的政府倡议。

竞争格局：生命科学产业人工智慧的一些主要市场参与者包括AiCure LLC、Apixio Inc.（Centene Corporation）、Atomwise Inc、Enlitic Inc.、International Business Machines Corporation、Insilico Medicine Inc.、Nuance Communications Inc.。 Inc.、Sensely Inc.、Sophia Genetics SA. 等。

挑战与机会：人工智慧和生命科学市场面临各种挑战，包括高昂的实施成本、需要更熟练的人工智慧专业人员以及对资料隐私和安全日益增长的担忧。生物资料的复杂性需要更复杂的人工智慧模型，而这可能很难开发。在机会方面，人工智慧在提高药物开发效率、降低成本和个人化患者护理方面显示出潜力。此外，新兴市场也存在巨大的成长潜力，人工智慧可以弥补医疗保健服务的差距。

生命科学市场趋势/驱动因素中的人工智慧：

药物发现与开发加速

传统的药物开发过程是一个漫长、成本高昂且往往效率低下的过程，需要十多年才能将新药推向市场。人工智慧透过加快药物开发的各个阶段来改变这一格局。例如，2023年，高知特在旧金山成立了高阶人工智慧（AI）实验室，主要专注于人工智慧核心研究、创新和尖端人工智慧系统的开发。该实验室由专门的人工智慧研究人员和开发人员组成，已获得 75 项已发布和正在申请的专利，并将与研究机构、客户和新创公司合作。机器学习演算法分析大量资料集，包括生物和化学资讯、临床试验资料和现有药物资料库，以前所未有的速度和准确性识别潜在的候选药物。这使得研究人员能够找出有前景的化合物，预测其功效并优化其特性，从而显着减少药物发现所需的时间和成本，从而推动人工智慧在生命科学市场的成长。

个人化医疗和保健

传统的医疗方法通常遵循一刀切的方法，根据广泛人群的平均水平开出药物和疗法。人工智慧利用巨量资料和机器学习的力量来分析个人的基因组成、临床病史、生活方式因素和即时健康资料，以製定高度客製化的治疗计划。 2023 年，OM1 推出了 PhenOM，这是一个由人工智慧驱动的个人化医疗平台，利用丰富的医疗数据集和人工智慧技术。 PhenOM 使用纵向健康史资料进行校准，识别与病情相关的独特数位表型，从而实现大规模的个人化医疗保健见解。 OM1 专注于慢性病，开创了创新的RWE 研究，对患者的治疗结果产生个人化的影响，并透过尖端的人工智慧解决方案推进医疗保健。而且不太可能导致不良副作用。此外，人工智慧驱动的预测模型可以帮助识别患有某些疾病的较高风险的患者，从而可以采取早期干预和预防措施。此外，在肿瘤学中，人工智慧有助于找出导致患者癌症的特定基因突变，使肿瘤学家能够推荐更有可能成功的标靶治疗。

疾病诊断和生物标记发现

人工智慧演算法可以分析多种医疗资料来源，包括 X 光、MRI 和 CT 扫描等医学影像、病患电子健康记录和基因组图谱，且具有极高的准确性和效率。在放射学中，人工智慧驱动的影像分析可以帮助放射科医生检测细微的异常并标记潜在的健康问题，有助于早期诊断和治疗。 2024 年，Rad AI 与 Google 合作，利用人工智慧技术增强放射学报告，旨在节省放射科医生的时间、减少倦怠并提高患者护理品质。此次合作将简化工作流程、自动化重复任务，并提高放射学报告的效率和准确性。此外，人工智慧有助于发现疾病生物标誌物，这对于在最早阶段识别疾病并监测其进展至关重要。机器学习模型可以检测分子资料中的微妙模式，帮助识别与各种疾病相关的特定生物标记物，包括癌症、阿兹海默症和心血管疾病。这些生物标记可以作为早期预警讯号，可以指导临床医生及时做出明智的病患照护决策。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：生命科学市场中的全球人工智慧

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品分类

  • 软体
    • 市场趋势
    • 市场预测
  • 硬体
    • 市场趋势
    • 市场预测
  • 服务
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依部署

  • 本地
    • 市场趋势
    • 市场预测
  • 基于云端
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按应用

  • 药物发现
    • 市场趋势
    • 市场预测
  • 医疗诊断
    • 市场趋势
    • 市场预测
  • 生物技术
    • 市场趋势
    • 市场预测
  • 临床试验
    • 市场趋势
    • 市场预测
  • 精准与个人化医疗
    • 市场趋势
    • 市场预测
  • 病人监护
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AiCure LLC
    • Apixio Inc. (Centene Corporation)
    • Atomwise Inc
    • Enlitic Inc.
    • International Business Machines Corporation
    • Insilico Medicine Inc.
    • Nuance Communications Inc.
    • NuMedii Inc.
    • Sensely Inc.
    • Sophia Genetics SA
Product Code: SR112024A6080

The global artificial intelligence in life sciences market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.4 Billion by 2032, exhibiting a growth rate (CAGR) of 22.4% during 2024-2032. The rising prevalence of complex diseases, the increasing adoption of AI in medical imaging analysis, the integration of AI into genomics research and analysis, and the convergence of AI with emerging technologies are some of the major factors propelling the market.

Artificial Intelligence in Life Sciences Market Analysis:

Major Market Drivers: Artificial intelligence in life sciences is mainly driven by the increase in the volume of biomedical data from genomic sequences and electronic health records which necessitates the incorporation of powerful AI tools for effective management and analysis. In line with this, artificial intelligence is instrumental in accelerating drug discovery and development processes thereby significantly reducing time and costs. Moreover, regulatory support for AI integration in clinical settings and advancements in machine learning and computational algorithms further propel artificial intelligence in life sciences market growth.

Key Market Trends: Key market trends in artificial intelligence in the life sciences sector include the integration of artificial intelligence along with cloud computing and Internet of Things (IoT) devices further enhancing data accessibility and real-time analysis. There is also a significant trend toward the development of AI-driven predictive models that forecast disease progression and patient outcomes improving clinical decision-making. In line with this, collaborative efforts between AI tech firms and pharmaceutical companies are on the rise mainly aimed at leveraging AI for drug development and patient monitoring. The growing focus on ethical AI and transparent algorithms to ensure patient data security and privacy compliance is another notable trend. Furthermore, the use of AI in robotic process automation (RPA) is a streamlining administrative task in healthcare further driving artificial intelligence in life sciences market growth.

Geographical Trends: Geographically, North America leads the artificial intelligence and life sciences market mainly driven by its advanced technological infrastructure, substantial investment in artificial intelligence and healthcare, and strong support from regulatory bodies. Europe follows closely, with significant growth because of the increase in the adoption of AI in healthcare systems and support from government policies regarding AI research and data protection. Asia Pacific is experiencing significant growth mainly fueled by increasing healthcare demands, technological advancements, and government initiatives to promote AI in countries like China, Japan, and India.

Competitive Landscape: Some of the major market players in the artificial intelligence in life sciences industry include AiCure LLC, Apixio Inc. (Centene Corporation), Atomwise Inc, Enlitic Inc., International Business Machines Corporation, Insilico Medicine Inc., Nuance Communications Inc., NuMedii Inc., Sensely Inc. Sophia Genetics SA., among many others.

Challenges and Opportunities: The artificial intelligence and life sciences market faces various challenges, which include high implementation costs, a need for more skilled artificial intelligence professionals, and growing concerns over data privacy and security. The complexity of biological data requires more sophisticated AI models, which can be difficult to develop. On the opportunity side, artificial intelligence shows potential in improving drug development efficiency, reducing costs, and in personalized patient care. Furthermore, there is also significant potential for growth in emerging markets where AI can address the gaps in healthcare services.

Artificial Intelligence in Life Sciences Market Trends/Drivers:

Drug Discovery and Development Acceleration

The traditional drug development process is a lengthy, costly, and often inefficient endeavour, taking over a decade to bring a new drug into the market. AI transforms this landscape by expediting various stages of drug development. For instance, in 2023, Cognizant launched an Advanced Artificial Intelligence (AI) Lab in San Francisco to mainly focus on core AI research, innovation, and development of cutting-edge AI systems. The lab, staffed by a team of dedicated AI researchers and developers, has already produced 75 issued and pending patents and will collaborate with research institutions, customers, and startups. Machine learning algorithms analyse vast datasets, including biological and chemical information, clinical trial data, and existing drug databases, to identify potential drug candidates with unprecedented speed and accuracy. This enables researchers to pinpoint promising compounds, predict their efficacy, and optimize their properties, significantly reducing the time and cost required for drug discovery, thereby propelling the artificial intelligence in life sciences market growth.

Personalized Medicine and Healthcare

Traditional medical treatments often follow a one-size-fits-all approach, with medications and therapies prescribed based on broad population averages. AI harnesses the power of big data and machine learning to analyze an individual's genetic makeup, clinical history, lifestyle factors, and real-time health data to develop highly tailored treatment plans. In 2023, OM1 introduced PhenOM, an AI-powered platform for personalized medicine, leveraging enriched healthcare datasets and AI technology. Calibrated using longitudinal health history data, PhenOM identifies unique digital phenotypes associated with conditions, enabling personalized healthcare insights at scale. With a focus on chronic conditions, OM1 pioneers innovative RWE research, delivering personalized impact on patient outcomes and advancing healthcare through cutting-edge AI solutions.This level of personalization ensures that patients receive treatments that are not only more effective but also less likely to cause adverse side effects. Also, AI-driven predictive models can help identify patients at higher risk of certain diseases, allowing for early intervention and preventive measures. Additionally, in oncology, AI assists in pinpointing the specific genetic mutations driving a patient's cancer, enabling oncologists to recommend targeted therapies that are more likely to be successful.

Disease Diagnosis and Biomarker Discovery

AI algorithms can analyze diverse medical data sources, including medical images, such as X-rays, MRIs, and CT scans, patient electronic health records, and genomic profiles, with exceptional accuracy and efficiency. In radiology, AI-powered image analysis can assist radiologists in detecting subtle abnormalities and flagging potential health issues, aiding in early diagnosis and treatment. In 2024, Rad AI has partnered with Google to enhance radiology reporting by leveraging AI technology, aiming to save radiologists time, reduce burnout, and improve patient care quality. This collaboration will streamline workflows, automate repetitive tasks, and advance the efficiency and accuracy of radiology reporting. Moreover, AI is instrumental in the discovery of disease biomarkers, which are crucial in identifying diseases at their earliest stages and monitoring their progression. Machine learning models can detect subtle patterns in molecular data, helping to identify specific biomarkers associated with various diseases, including cancer, Alzheimer's, and cardiovascular conditions. These biomarkers serve as early warning signs and can guide clinicians in making timely and informed decisions about patient care.

Artificial Intelligence in Life Sciences Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global artificial intelligence in life sciences market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on offering, deployment, and application.

Breakup by Offering:

Software

Hardware

Services

Software dominates the market

The report has provided a detailed breakup and analysis of the market based on the offering. This includes software, hardware, and services. According to the report, software represented the largest segment.

Software in the context of AI encompasses a wide array of tools, platforms, and applications specifically designed to process, analyze, and interpret the immense volume of data generated in life sciences research. These software solutions utilize machine learning algorithms, natural language processing, deep learning, and other AI techniques to sift through complex biological datasets, making sense of genomics, proteomics, and clinical data. The versatility of AI software allows researchers to explore various aspects of drug discovery, disease diagnosis, and patient care with unprecedented precision and efficiency. Additionally, the scalability and adaptability of AI software make it a preferred choice for organizations operating in the life sciences domain. Researchers can customize and fine-tune AI algorithms to meet their specific research needs, whether it involves drug target identification, biomarker discovery, or patient stratification for clinical trials. This flexibility empowers scientists to adapt to evolving research objectives and swiftly respond to emerging challenges in healthcare and life sciences. Furthermore, AI software offerings are at the forefront of addressing some of the most pressing issues in the industry.

Breakup by Deployment:

On-premises

Cloud-based

Cloud-based dominate the market

The report has provided a detailed breakup and analysis of the market based on the deployment. This includes on-premises and cloud-based. According to the report, cloud-based represented the largest segment.

Cloud-based deployment offers unparalleled scalability and flexibility, which are crucial for the resource-intensive nature of AI applications in life sciences. Researchers and organizations can tap into cloud resources as needed, scaling up or down depending on the complexity and volume of data being processed. This dynamic scalability ensures that computational resources are optimally allocated, avoiding underutilization or resource bottlenecks, which can occur with on-premises solutions. Additionally, cloud-based deployment eliminates the need for significant upfront hardware and infrastructure investments. This cost-effectiveness is particularly attractive for research institutions, pharmaceutical companies, and healthcare providers looking to leverage AI without the burden of substantial capital expenditures. Cloud services provide pay-as-you-go pricing models, allowing organizations to pay only for the computing resources they consume, thus optimizing cost management. Moreover, cloud-based deployments offer the advantage of accessibility and collaboration. Researchers and scientists can access AI tools and applications from anywhere with an internet connection, facilitating collaboration across geographic boundaries and enabling real-time data sharing and analysis.

Breakup by Application:

Drug Discovery

Medical Diagnosis

Biotechnology

Clinical Trials

Precision and Personalized Medicine

Patient Monitoring

Drug discovery dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes drug discovery, medical diagnosis, biotechnology, clinical trials, precision and personalized medicine, and patient monitoring. According to the report, drug discovery represented the largest segment.

AI-driven drug discovery is not limited to target identification alone. AI models can predict the pharmacokinetics and toxicity profiles of potential drugs, allowing researchers to assess their safety and efficacy earlier in the development pipeline. This risk mitigation not only saves time but also reduces the likelihood of costly late-stage failures, a common challenge in the pharmaceutical industry. Additionally, AI plays a pivotal role in drug repurposing, where existing drugs are explored for new therapeutic applications. By analyzing biological data, AI algorithms can identify overlooked connections between drugs and diseases, potentially unveiling novel treatment options. This approach not only accelerates the availability of treatments for various medical conditions but also leverages existing knowledge and resources more efficiently. Furthermore, the personalized medicine revolution is closely linked to AI-driven drug discovery. As AI models analyze patients' genetic profiles, clinical histories, and real-time health data, they can identify specific genetic markers and mutations that influence drug response.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest artificial intelligence in life sciences market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts significant investments in AI research and development. Government initiatives, private sector funding, and venture capital investments have poured into AI projects and startups, fueling innovation and technological advancements. This financial backing has accelerated the growth of AI-driven solutions, from drug discovery and genomics to healthcare analytics and personalized medicine. Moreover, North America's robust regulatory framework and intellectual property protection create a conducive environment for AI development and commercialization. Several regulatory agencies have been proactive in engaging with AI developers to establish clear guidelines and approval processes for AI-based medical devices and treatments. This regulatory clarity gives businesses confidence to invest in AI projects. Furthermore, North America's healthcare infrastructure is among the most advanced globally, making it a prime testing ground for AI applications. The region's large patient population, extensive electronic health record systems, and well-established pharmaceutical and biotech industries provide ample opportunities for AI-driven healthcare solutions to demonstrate their efficacy and impact.

Competitive Landscape:

Numerous companies in this market are focused on using AI to accelerate drug discovery processes. They develop AI algorithms and platforms that analyze biological data, identify potential drug candidates, predict drug interactions, and optimize drug design, all with the goal of bringing new therapies to market faster and more efficiently. Also, AI companies in the life sciences sector work on solutions for genomic analysis. They develop tools that can decipher and interpret genetic information, identify disease markers, predict disease risk, and enable personalized medicine by tailoring treatments based on an individual's genetic profile. Moreover, companies are developing AI-driven solutions that assist radiologists and pathologists in interpreting medical images such as X-rays, MRIs, and CT scans. These tools can help detect diseases and anomalies earlier and with greater accuracy. Companies are also actively engaged in predictive analytics, utilizing AI to identify disease biomarkers, predict patient outcomes, and stratify patients for clinical trials. These AI-driven insights can inform treatment decisions and improve patient care.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AiCure LLC

Apixio Inc. (Centene Corporation)

Atomwise Inc

Enlitic Inc.

International Business Machines Corporation

Insilico Medicine Inc.

Nuance Communications Inc.

NuMedii Inc.

Sensely Inc.

Sophia Genetics SA

(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)

Artificial Intelligence in Life Sciences Market Recent Developments:

In 2024, Atomwise's AIMS initiative showcased the AtomNet AI Platform's success in discovering novel chemical matter for 235 out of 318 targets, demonstrating its potential as an alternative to high-throughput screening. The study, published in Nature Scientific Reports, highlighted AtomNet's ability to identify hits across various protein classes, emphasizing its broad applicability in drug discovery.

In 2024, IBM, in collaboration with the Government of Canada and Quebec, signed agreements to enhance Canada's semiconductor industry with a significant investment of around CAD 187 million, focusing on advancing chip packaging capabilities and boosting R&D at IBM Canada's Bromont plant. This initiative aims to create high-paying jobs, strengthen supply chains, and position Canada at the forefront of semiconductor innovation, as emphasized by Prime Minister Justin Trudeau and industry leaders.

Key Questions Answered in This Report

  • 1. How big is the global artificial intelligence in life sciences market?
  • 2. What is the expected growth rate of the global artificial intelligence in life sciences market during 2024-2032?
  • 3. What are the key factors driving the global artificial intelligence in life sciences market?
  • 4. What has been the impact of COVID-19 on the global artificial intelligence in life sciences market?
  • 5. What is the breakup of the global artificial intelligence in life sciences market based on the offering?
  • 6. What is the breakup of the global artificial intelligence in life sciences market based on the deployment?
  • 7. What is the breakup of the global artificial intelligence in life sciences market based on the application?
  • 8. What are the key regions in the global artificial intelligence in life sciences market?
  • 9. Who are the key players/companies in the global artificial intelligence in life sciences market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Artificial Intelligence In Life Sciences Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Offering

  • 6.1 Software
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hardware
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Deployment

  • 7.1 On-premises
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloud-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Drug Discovery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Medical Diagnosis
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Biotechnology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Clinical Trials
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Precision and Personalized Medicine
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Patient Monitoring
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AiCure LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Apixio Inc. (Centene Corporation)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Atomwise Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Enlitic Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 International Business Machines Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Insilico Medicine Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Nuance Communications Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 NuMedii Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sensely Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sophia Genetics SA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials

List of Figures

  • Figure 1: Global: Artificial Intelligence In Life Sciences Market: Major Drivers and Challenges
  • Figure 2: Global: Artificial Intelligence In Life Sciences Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Artificial Intelligence In Life Sciences Market: Breakup by Offering (in %), 2023
  • Figure 5: Global: Artificial Intelligence In Life Sciences Market: Breakup by Deployment (in %), 2023
  • Figure 6: Global: Artificial Intelligence In Life Sciences Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Artificial Intelligence In Life Sciences Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Artificial Intelligence In Life Sciences (Software) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Artificial Intelligence In Life Sciences (Software) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Artificial Intelligence In Life Sciences (Hardware) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Artificial Intelligence In Life Sciences (Hardware) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Artificial Intelligence In Life Sciences (Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Artificial Intelligence In Life Sciences (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Artificial Intelligence In Life Sciences (On-premises) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Artificial Intelligence In Life Sciences (On-premises) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Artificial Intelligence In Life Sciences (Cloud-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Artificial Intelligence In Life Sciences (Cloud-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Artificial Intelligence In Life Sciences (Drug Discovery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Artificial Intelligence In Life Sciences (Drug Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Artificial Intelligence In Life Sciences (Medical Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Artificial Intelligence In Life Sciences (Medical Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Artificial Intelligence In Life Sciences (Biotechnology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Artificial Intelligence In Life Sciences (Biotechnology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Artificial Intelligence In Life Sciences (Clinical Trials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Artificial Intelligence In Life Sciences (Clinical Trials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Artificial Intelligence In Life Sciences (Precision and Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Artificial Intelligence In Life Sciences (Precision and Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Artificial Intelligence In Life Sciences (Patient Monitoring) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Artificial Intelligence In Life Sciences (Patient Monitoring) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Artificial Intelligence In Life Sciences Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Artificial Intelligence In Life Sciences Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Artificial Intelligence In Life Sciences Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Artificial Intelligence In Life Sciences Industry: SWOT Analysis
  • Figure 80: Global: Artificial Intelligence In Life Sciences Industry: Value Chain Analysis
  • Figure 81: Global: Artificial Intelligence In Life Sciences Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Artificial Intelligence In Life Sciences Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Artificial Intelligence In Life Sciences Market Forecast: Breakup by Offering (in Million US$), 2024-2032
  • Table 3: Global: Artificial Intelligence In Life Sciences Market Forecast: Breakup by Deployment (in Million US$), 2024-2032
  • Table 4: Global: Artificial Intelligence In Life Sciences Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Artificial Intelligence In Life Sciences Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Artificial Intelligence In Life Sciences Market: Competitive Structure

Table 7 Global: Artificial Intelligence In Life Sciences Market: Key Players